Boston Scientific Successfully Completes €1.5 Billion Senior Notes Offering

Boston Scientific Secures €1.5 Billion in Senior Notes

Boston Scientific Corporation, listed on NYSE as BSX, announced a successful completion of its public offering of senior notes recently. Conducted by American Medical Systems Europe B.V. (AMS Europe), a fully owned subsidiary of the corporation, the offering encompassed a significant aggregate principal amount of €850 million in 3.000% notes due in 2031, alongside €650 million in 3.250% notes set to mature in 2034.

The total for this offering reached an impressive €1.5 billion, which is anticipated to be a key financial maneuver for the company. Each of these notes comes with an unconditional guarantee from Boston Scientific itself. This strategic initiative follows the company's plans to enhance its financial stability and growth opportunities in the future.

Purpose of the Offering

Boston Scientific aims to utilize the proceeds from this offering, combined with its own available cash, for a variety of corporate purposes. Primarily, the company intends to repay AMS Europe's existing senior notes, which have an interest rate of 0.750% due on March 8, 2025. Furthermore, the funds will cover any accrued and unpaid interest related to those notes.

In addition to repaying debts, the capital raised will also support general corporate needs, which may include short-term investments, working capital funding, and potentially future acquisitions. Such applications are indicative of a proactive approach by Boston Scientific in managing its financial health and operational capacity.

About Boston Scientific

With a history spanning over 45 years, Boston Scientific has established itself as a leader in the medical technology sector. The company is dedicated to enhancing patients' lives through the development of innovative technologies that improve health outcomes worldwide. Their expansive portfolio includes devices and therapies that aid healthcare providers in diagnosing and treating a wide array of complex diseases across multiple fields, including cardiovascular, respiratory, digestive, and urological health.

Boston Scientific continues to focus on advancing scientific innovation for life, emphasizing the reduction of healthcare costs while fulfilling unmet patient needs. Interested parties can find more information about their offerings on their official website or connect with them via LinkedIn and X, formerly known as Twitter.

Forward-Looking Statements

In the company's public statements, Boston Scientific has included caution regarding forward-looking statements. These statements may pertain to future projections and are based on the company's current beliefs and estimates using available information. Thus, actual outcomes may differ due to various unpredictable factors such as economic conditions, currency fluctuations, regulatory challenges, and market competition.

Investors and stakeholders are advised to consider these uncertainties and should not place undue reliance on the company's forecasts. As Boston Scientific navigates its evolving landscape, they remain committed to transparent communication and strategic growth, consistently prioritizing innovative solutions to improve patient care.

For inquiries regarding Boston Scientific and its announcements, please contact the media relations or investor relations teams directly, as outlined in their communications.